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Abstract: 
Astaxanthin (AXN) is known to have health benefits by epidemiological studies. Therefore, it is of interest to assess the effect of AXN 
(derived from indigenous unicellular green alga Haematococcus lacustris) to modulate cell cycle arrest, lysosomal acidification and 
eventually apoptosis using in vitro in A549 lung cancer cells. Natural extracts of astaxanthin were obtained by standardized methods as 
reported earlier and characterized by standard HPLC and MS. Treatment of A549 cells with AXN (purified fraction) showed significant 
reduction in cell viability (about 50%) as compared to crude extract at 50µM concentration. Thus, we show the anticancer effects and 
lysosomal acidification in A549 cells by Astaxanthin from Haematococcus lacustris for further consideration. Together, our results 
demonstrated the anticancer potential of AXN from Haematococcus lacustris, which is found to be mediated via its ability to induce cell cycle 
arrest, lysosomal acidification and apoptotic induction. 
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Background: 
Haematococcus lacustris (formerly called as Haematococcus pulvialis) is 
a freshwater microgreen alga with intirinsic antioxidant property 
and is reported to confer numerous health benefits [1,2]. 
Astaxanthin (AXN) (3, 3′-dihydroxy-ß, -ß, carotene 4,4′-dione) is a 
pigmented carotenoid antioxidant with high biological activity 
given its potential in food and pharmaceutical industries, as well as 
in feed industry for the ability to pigment and improve survival 
rate of aquatic animals. H. lacustris has been used preferably to 
produce astaxanthin from natural sources, and is known to possess 
high content of astaxanthin at about 5%, of its dry weight (DW) [3]. 
Furthermore, the structure of astaxanthin from H. lacustris is similar 
to those in salmon and other aquatic organisms, making 
astaxanthin more easily to be absorbed. As a result, many efforts 
have been focused on production of astaxanthin-rich H. lacustris to 
exploit its benefits to promote human health and as well in 
industrial applications [4]. Astaxanthin (AXN) from various 
microalgae and yeast has been approved by United States FDA as a 
neutraceutical and also as a nutraceutical supplement for about 15 
years [5,6]. Studies using various in vitro and animal models 
documented significant health benefits including mediating 
immune response [7], inhibiting growth of colorectal cancer cells 
[8], improving rodent memory functions [9] and protection against 
UV rays mediated photooxidation, antioxidant and anti-
inflammatory functions [2]. In addition, reports suggest that the 
unique structural properties of AXN endure it to span cell 
membrane and quenches free radicals thereby serving as a better 
pharmaceutical agent [10,11]. Notably, natural AXN has been 
shown to cross blood brain barrier (BBB) and exerts protections 
against various neurological disorders including Alzheimers 
Disease (AD) [12] and inhibits growth of various tumors including 
fibrosarcoma, breast, and prostate cancer cells [8,13]. However, 
most of the reported correlated the beneficial effects of natural AXN 
for its antioxidant activity and the mechanistic insight underlying 
natural AXN remains largely unknown. Therefore, it is of interest 
to assess the effect of AXN (derived from indigenous unicellular 
green alga Haematococcus lacustris) to modulate cell cycle arrest, 
lysosomal acidification and eventually apoptosis using in vitro in 
A549 lung cancer cells. 
 
Materials and Methods: 
Chemicals and Reagents: 
Propidium iodide (PI), Acridine orange (AO), Ethidium bromide 
(ETBR) and Dimethyl sulfoxide (DMSO), 3-[4, 5-Dimethyl-2-
thiazolyl]- 2,5-diphenyl tetrazolium bromide (MTT) and Acridine 
orange (AO), ethidium bromide (ETBR) were purchased from 
Sigma (St. Louis, MO, USA). PMI 1640 medium, fetal bovine serum 
(FBS) was purchased from Gibco (Carlsbad, CA, USA). FBS was 
stored at −20°C and then freshly prepared aliquots were used for 
cell culture complete medium. All the other chemicals used were of 
analytical grade unless otherwise stated. 
 
Extraction of Astaxanthin: 
The two litre of 30 days old culture of H. lacustris grown in BBM 
medium was taken and centrifuged at 10,000 rpm for 15 minutes. 
After centrifugation, the supernatant was decanted and the pellets 
were homogenized in a mortar and pestle using 100% acetone in 
the ratio of 1:10 v/v and then centrifuged at 8,000 rpm for 10 
minutes. The supernatant containing pigments was retained and 
the pellet was again homogenized in fresh solvent and 
subsequently centrifuged until the cell pellets became colorless. The 
combined extracts were concentrated with rotary evaporator at 
60oC. The dry solid residue was re-dissolved in acetone for 
subsequent separation such as TLC and column chromatography 
technique and the different elutes of the sample were confirmed by 
spectral and analytical methods with authentic astaxanthin. 
 
HPLC analysis:   
The samples were analyzed using LC20AD HPLC (SHIMADZU, 
Japan) equipped with binary pump, auto sampler and fully 
automated computer-controlled system with Lab solution 
chromatography workstation for data analysis. Astaxanthin was 
separated by chromatographic column inert sustain swift C-18, 
4.6mmx150mm- 3µm, (GL sciences Inc.). 20µl volume was injected 
with 1ml/min flow rate at 25°C column temperature under 474nm 
wavelength with mobile phase consists of 
acetonitrile/methanol/dichloromethane (80:15:5, v/v/v). 
 
MALDI-LC/MS analysis: 
Mass spectra using MALDI-LC/MS ((Bruker Daltonics) with 
spectrometer, equipped with a nitrogen laser (l = 337 nm), operated 
in reflectron, positive ion mode. a-cyano-4-hydroxy-cinnamic acid 
used as the matrices with three independent sample spotting along 
with Astaxanthin standard samples in ratio of 1:1 (0.5µl of sample: 
0.5µl of matrix) were spotted on stainless steel MALDI-LC/MS 324 
well plate from Bruker Daltonics.  
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Cell line and culture:  
Human lung cancer cell line A549 were purchased from National 
centre for cell science (NCCS), Pune. Cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) and 1% Antibiotic-Penicillin 
streptomycin solution. Cells were maintained at a controlled 
condition of 5% CO2, and 95% humidity. Experiments were 
performed in 6-well plates and 96 well plates unless stated 
otherwise. Cells were seeded   at a density of 1 × 106 and 1 × 104 
cells per well and incubated for 24 h prior to the experiments. The 
cells were washed with (phosphate buffered saline, pH 7.4) PBS 




Effect of AXN (dose dependent) on cell viability was measured 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium 
bromide dye reduction was performed according to our pervious 
procedure [14]. Finally, the concentrations of AXN resulting in 50% 
reduction in cell viability at 24h (i.e., 50µM/ml) were then 
calculated and were used for further experiments. Results were 
expressed as mean of three independent experiments. 
 
Acridine orange Ethidium bromide staining: 
AO/EB double staining was performed using standardized 
methods as previously reported [15]. A549 cells from all the 
experimental groups were stained using AO (4 µg/ml) and ETBR (4 
µg/ml) for 15 min. Followed by incubation-stained cells were 
examined under the fluorescence microscope using red and green 
filters. Viable cells will exhibit uniform bright green nuclei denoting 
normal structure, whereas early apoptotic cells will exhibit green 
nuclei, but will be more condensed. Late apoptotic cells will show 
orange to red nuclei with condensed chromatin, while the necrotic 
cells will show orange to red nuclei with basal chromatin levels. 
 
Statistical analysis: 
All the experiments were performed independently as triplicates 
(n=3). The mean ± standard deviation (SD) was determined for each 
group. One-way analysis of variance (one-way ANOVA) and 
Tukeys’ test was used for statistical analysis. Statistical value of p 




Identification and Characterization of AXN: 
The extracted AXN (Crude & Purified) from H. lacustris was 
identified, characterized, validated and finally confirmed with 
MALDI-LC/MS and HPLC analysis. The structure and molecular 
weight based characterization and determination of sample content 
between crude and purified AXN was clearly mentioned in Figure 
1 & 2. In order to characterization of AXN, the levels of stability, 
linearity, precision and reproducibility and refractory period of 
experiments were followed by standard analytical laboratory 
procedure.   
 
Cytotoxicity assay: 
Treatment of crude and AXN purified fractions from H. lacustris 
induced significant (P<0.05) cell death in A549 lung cancer cells. 
Cell death was observed within 24 hours of treatment with the 
crude and purified fractions of AXN, while control AXN (standard) 
was also producing similar cell death at 50 µM treatment 
concentrations in both the cell lines studied (Figure 3A). 
 
AXN induces nuclear morphology changes by lysosomal 
acidification:  
Considering that AXN induces a G2/M phase arrest blocking the 
progression of cell growth and replication, it is obvious to expect 
deregulated orchestration in the intracellular organelle functions 
including lysosomes. Indeed, Lysosomes are reported to play 
important role in all forms of cell deaths (apoptosis, autophagy and 
necrosis) associated with cancer [16]. We evaluated the changes in 
lysosomal acidification using acridine orange staining in A549 cells 
treated with crude and purified AXN fraction from H. lacustris and 
compared it with control and pure AXN positive control. The 
staining revealed that both purified AXN fraction and positive 
controls induced significant (P< 0.05) lysosomal acidification as 
observed by the increase in red intensity within the cells (Figure 
3B).  
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Figure 1: The HPLC analysis of astaxanthin extracted samples: crude (B), purified (C) from H. lacustris and standard astaxanthin substance 
(A) with respective of three independent experiments.  
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Figure 2: MALDI-LC/MS spectra with matrices of (a) unknown compound isolated and purified from H. lacustris and (b)standard AXN 
substance were observed in LC/MS. A peak at m/z at 596 ~ 597 has shown from both unknown and known standard of AXN.  
 
Discussion: 
Cancer mediated death in global population remains at top for 
several decades while there is continuous approval for array of 
anticancer drugs by FDA. About 59 new drugs in 2018 and 46 new 
drugs in 2017 were approved by FDA, denotes the need for new 
therapies that can reduce oncology-associated pathologies [17]. 
Though there are several synthetic drugs that hit global market for 
oncology therapies, imputability of adverse reactions of the same 
remains inevitable [18]. Hence, the avenue for safer anticancer 
drugs with minimal adverse reactions remains open and the agents 
derived from natural sources possess significant benefits as evident 
from accumulating reports [19,20]. AXN from H. lacustris has been 
known to possess diverse biological functions including anticancer 
actions. Other studies using AXN from natural sources already 
documented its anticancer effects against breast [21], Oral [22], 
bladder [23], colon [24] and liver [25] however its underlying 
mechanisms remain to be elucidated. Here we have attempted to 
investigate the effect of AXN on cell cycle arrest and cellular 
organelle dysfunction which can be attributed to its anti cancer 
activity. Although, many carotenoids have been reported to exert 
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anti cancer and antiproliferative effects, its potential use at clinical 
stages need to be validated. This could be due to the fact that 
studies so far conducted failed to establish how AXN affects 
cellular process or to establish a single prime mode of its anti-
cancer action. 
In this study AXN treatment altered viability of A549-lungcancer 
cells. Viability was reduced upto 50% at 50µM concentration of 
purified AXN. However, time kinetics of purified AXN did not 
show any changes in loss of viability after 24 hrs (Data not shown).  
 
 
Figure 3 (A) Shows the cell viability analysis by MTT assay. A549 cells were seeded onto each well and allowed to grow overnight. Cells 
were treated with various concentration of AXN (crude, Purified and standard AXN) for 24 h and the inhibitory concentration (IC50) was 
determined. Experiments were performed in triplicates, representative images were presented here and the results were expressed as mean 
± SD of 3 experiments. * Denotes significant difference from control by student’s t-test (p < 0.01). (B) Shows status of lysosomal acidification 
(via pore formation and cytotoxicity) in A549 cells. Cells were treated with and without AXN 50 µM (crude, Purified and standard AXN) 
for 24 h. Control and AXN treated cells were stained with AO/ETBR and the dual staining was examined under fluorescence microscopy 
(AO: excitation wavelength: 490nm and emission wavelength: 640nm). (ETBR excitation wavelength: 520nm and emission wavelength: 
600nm). Presence of bright red fluorescence indicates lysosomal acidification. Results are expressed as mean ± SD for 3 independent 
experiments. * denotes significant difference from control by student’s t-test (p < 0.01). Magnification: X20, Scale bar: 50µM.  
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Studies using other plant-derived carotenoids have shown they 
inhibit cell cycle progression and mediate cell cycle arrest, 
particularly in the G0/G1 phase of cell cycle [26,27]. Our results 
showed that AXN treatment to A549 cells caused accumulation of 
cells in G0/G1 phase, concomitantly reducing the total percentage 
of cells in G2/M phase as well. Considering the similarities with 
other studies, it is found that AXN ability to mediate cell viability 
loss is associated with cell cycle arrest and inhibition of cell 
proliferation. Similar to our results many studies have correlates 
the antitumor efficacy of carotenoids for its ability to mediate cell 
cycle arrest [28,29]. This suggest that cell cycle arrest might be a 
initial mode of mechanism of antitumor action of AXN as reported 
in other cancer cells like colon and prostate cells [29,30]. Further to 
elucidate the phenomenon that lies behind AXNs ability to mediate 
cell cycle arrest, we have analyzed the status of cellular organelle 
dysfunction in A549 cells upon AXN treatment. Indeed, lysosomes 
are critically noted as a crucial cellular organelle during treatment 
with various anticancer drugs, as it contains numerous hydrases 
that can be to degrade intra and extracellular materials and is 
implicated in cell death [31,32]. Notably, involvement of 
lysososmes in cell death has been overlooked because lysosomal 
membrane permeabilization (LMP) due to lysosomal acidification 
does not alter its ultrastructure [33]. Perhaps, studies involving 
LMP has been recently focused due to development of more assays 
that analyze LMPs. Various stimuli such as lysosomotrophic 
detergents, viral proteins, bacterial and fungal toxins, proteases, 
lipid and lipid metabolites, and notably ROS were known to 
modulate LMP thereby causing lysosomal acidification and 
eventually cell death [34]. In this study, treatment with AXN to 
A549 cells causes significant increase in acridine orange (AO) 
staining denotes increased number of acidic autolysosomes as 
revealed by Fluorescent microscopic analysis. This denotes that 
AXN mediates lysosomal acidification and thereby causing loss of 
LMP and releasing cath D hydrolytic enzymes that can act along 
with caspases to mediate apoptotic cell death. The observed 
increase in lysosome acidification can be attributed to ability of 
AXN to generate ROS in cancer cells and can be correlated to its 
anticancer function. Here we are the first to report AXN induces 
lysosomal acidification in A549 cells and can be prime mechanism 
by which it exerts anti cancer role. 
 
Conclusion: 
We show the anticancer effects and lysosomal acidification in A549 
cells by Astaxanthin from Haematococcus lacustris for further 
consideration. 
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